Latest 3 stories · newest May 28, 2026
Immunic announced presentation of three posters at the CMSC Annual Meeting showcasing additional Phase 2 CALLIPER trial data for vidofludimus calcium in progressive multiple sclerosis, including a late-breaking analysis introducing novel statistical methods for measuring disability changes. The data…
IMMUNIC, INC. has entered into an employment agreement with Erik Lundgren to serve as CEO effective May 22, 2026. The appointment represents a leadership change for the biopharmaceutical company.
Immunic appointed biopharmaceutical veteran Michael Bonney as Chair of the Board, effective May 16, 2026, replacing interim chair Simona Skerjanec who remains as director. Bonney brings 30+ years of industry experience including leadership at Biogen during Avonex's MS launch and prior CEO role at Cu…
The same IMUX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/IMUX/newsSTART FREE